|Bid||50.110 x 800|
|Ask||50.120 x 300|
|Day's Range||49.970 - 50.250|
|52 Week Range||36.810 - 50.250|
|PE Ratio (TTM)||11.91|
|Dividend & Yield||1.64 (3.34%)|
|1y Target Est||N/A|
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
Alnylam gapped up Wednesday — to Ionis' detriment — after reporting positive results in a late-stage trial of a drug to treat a rare disease.